The FINANCIAL — Novo Nordisk is investing 1.5 billion Danish kroner in a new 7,500 m2 facility in Kalundborg, Denmark. The facility will produce active pharmaceutical ingredients for NovoSeven and future products for treating haemophilia.
The investment is estimated to create 100 new production and engineering jobs in Kalundborg, where Novo Nordisk currently employs more than 2,800 people, according to Novo Nordisk.
“The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees,” said Henrik Wulff, executive vice president, Product Supply, Novo Nordisk.
Groundbreaking will take place today, 4 May, and the facility is expected to be approved and fully operational in 2020.
Discussion about this post